To give a nod to Leronlimab in this whole discussion, Remdesivir, at least in the charts I’ve seen, fared slightly worse over 28 days on viral load. So yes, my belief is that Leronlimab will work better. But only hardline data will secure that statement is all I’m saying.
It was definitely in one of the last 2 calls. If you recall he said Remdesivir treats just the viral but Leronlimab treats much more. He just said it wasn’t needed. If it were better he would have suggested that it was needed by Leronlimab in a combo. He must’ve felt that Leronlimab was just as good as a viral inhibitor or he would have said it was needed in treatment. That’s how I interpreted it. If you didn’t hear that then you haven’t been following it lately.
Market Data 
Markets 
AI
